Literature DB >> 3110303

Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in infants.

H Hilpert, H Brüssow, C Mietens, J Sidoti, L Lerner, H Werchau.   

Abstract

The use of a concentrate containing milk immunoglobulins prepared from rotavirus-hyperimmunized cows (neutralization titer, 1:6,000 for a 10% solution) to treat infants hospitalized for acute rotavirus gastroenteritis resulted in a significant (P = .008) reduction in the duration of excretion of virus. Stool samples from treated infants showed the presence of bovine milk immunoglobulins in 47% of cases and of neutralizing activity in 43% (mean neutralization titer, 1:48); stool samples from control infants showed neutralizing activities in only 3% of cases (neutralization titers, less than 1:20). Immunoelectrophoresis of stool extracts revealed fragment A, a bovine analogue of F(ab')2 or Fab, as the major product of in vitro and in vivo digestion of the immunoglobulins. Cessation of excretion of virus correlated with the appearance of neutralizing activities in 19 of 25 infants. Only concentrate-treated infants with high neutralizing activity in stools showed a statistically significant reduction in duration of excretion of virus; this duration in concentrate-treated infants with low neutralizing activity was comparable with controls.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3110303     DOI: 10.1093/infdis/156.1.158

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  40 in total

Review 1.  Passive immunity against human pathogens using bovine antibodies.

Authors:  C Weiner; Q Pan; M Hurtig; T Borén; E Bostwick; L Hammarström
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 2.  Oral immunoglobulin for the prevention of rotavirus infection in low birth weight infants.

Authors:  Mohan Pammi; Khalid N Haque
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

3.  Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate.

Authors:  D M Lyerly; E F Bostwick; S B Binion; T D Wilkins
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

4.  Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion.

Authors:  Blaise Corthésy; Yann Benureau; Clémentine Perrier; Cynthia Fourgeux; Nathalie Parez; Harry Greenberg; Isabelle Schwartz-Cornil
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

Review 5.  Past, present, and future technologies for oral delivery of therapeutic proteins.

Authors:  Rajesh Singh; Shailesh Singh; James W Lillard
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

Review 6.  Rotavirus gene structure and function.

Authors:  M K Estes; J Cohen
Journal:  Microbiol Rev       Date:  1989-12

Review 7.  Treatment of traveller's diarrhoea. Economic aspects.

Authors:  M A Thomson; I W Booth
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

Review 8.  Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections.

Authors:  D Carlander; H Kollberg; P E Wejåker; A Larsson
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

9.  Bovine colostral antibody against verotoxin 2 derived from Escherichia coli O157:H7: resistance to proteases and effects in beagle dogs.

Authors:  Takashi Kuribayashi; Tetsuro Seita; Mariko Matsumoto; Katsunori Furuhata; Kazutoshi Tagata; Shizuo Yamamoto
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

10.  Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.

Authors:  C P Kelly; C Pothoulakis; F Vavva; I Castagliuolo; E F Bostwick; J C O'Keane; S Keates; J T LaMont
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.